Myasthenia Gravis
Welcome,         Profile    Billing    Logout  
 64 Companies   21 Products   21 Products   23 Mechanisms of Action   207 Trials   10745 News 


«12...3435363738394041424344...136137»
  • ||||||||||  Uplizna (inebilizumab-cdon) / Mitsubishi Tanabe, Amgen
    Trial completion date, Trial primary completion date:  MINT: Myasthenia Gravis Inebilizumab Trial (clinicaltrials.gov) -  Jun 22, 2023   
    P3,  N=270, Recruiting, 
    Trial completion date: Dec 2024 --> Mar 2029 | Trial primary completion date: Jun 2023 --> Oct 2024
  • ||||||||||  Review, Journal, Checkpoint inhibition:  Cardiovascular Toxicity of Immune Checkpoint Inhibitors: A Guide for Clinicians. (Pubmed Central) -  Jun 21, 2023   
    Cardiovascular toxicity, especially myocarditis, emerged as a life-threatening irAE in the real-word setting, and the European Society of Cardiology has recently published the first guideline on cardio-oncology to increase awareness and promote a standardized approach to tackle this complex multimodal issue, including diagnostic challenges, assessment, treatment, and surveillance of patients with cancer receiving ICIs. In this article, through a question & answer format made up of case vignettes, we offer a clinically oriented overview on the latest advancements of ICI-related cardiovascular toxicity, focusing on myocarditis and associated irAEs (myositis and myasthenia gravis within the so-called overlap syndrome), with the purpose of assisting clinicians and healthcare professionals in daily clinical practice.
  • ||||||||||  Soliris (eculizumab) / AstraZeneca, Opdivo (nivolumab) / Ono Pharma, BMS, Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
    Journal:  Global research hotspots and frontiers of myasthenia gravis from 2002 to 2021: A bibliometric study. (Pubmed Central) -  Jun 20, 2023   
    The study also identified pathogenesis, eculizumab, thymic epithelial cells, immune checkpoint inhibitors, thymectomy, MuSK antibodies, risk, diagnosis, and management as the current hot research topics in MG, while burst keywords like quality of life, immune-related adverse events (irAEs), rituximab, safety, nivolumab, cancer, and classification indicated the frontiers of MG research. This study effectively identifies the hotspots and frontiers of MG research, and offers valuable references for researchers interested in this area.
  • ||||||||||  Journal:  Grace Face Sign in Generalized Myasthenia Gravis (MG). (Pubmed Central) -  Jun 20, 2023   
    This study effectively identifies the hotspots and frontiers of MG research, and offers valuable references for researchers interested in this area. No abstract available
  • ||||||||||  Journal, Metabolomic study:  UPLC-HRMS-based Plasma Metabolomics Study of Thymoma and Thymic Hyperplasia. (Pubmed Central) -  Jun 19, 2023   
    Our study revealed aberrant aromatic amino acid metabolism and fatty acid oxidation might be associated with thymoma. The identified unique metabolic characteristics of thymoma may provide valuable information for study of the molecular mechanism of thymoma pathogenesis, and improvement of diagnosis and discovery of new therapeutic strategies for thymoma.
  • ||||||||||  DIAPHRAGMATIC CONTRACTION SPEED AT FOLLOW-UP OF PATIENTS ADMITTED FOR MYASTHENIA GRAVIS (PS-20 in poster area) -  Jun 17, 2023 - Abstract #ERS2023ERS_1905;    
    After statistical analysis, we observed differences in (((v10-v1)/v1))x100) between the group of patients who required mechanical ventilation (and were classified as myasthenic crisis) vs the group of patients who did not require NIV (p= 0.0018). (figure 2) The percentage of change in diaphragmatic contraction velocity after repeated snip maneuvers may be an indicator of diaphragm fatigability in patients with MG and may be useful in determining the need for ventilation in these patients.; Pulmonary rehabilitation; Endoscopy and interventional pulmonology; Epidemiology; Public health; Surgery; Imaging; General respiratory patient care; Respiratory intensive care
  • ||||||||||  Genetic predisposition for low functional status in COPD (PS-3 in poster area) -  Jun 17, 2023 - Abstract #ERS2023ERS_1563;    
    FAM177A1 has been linked to myasthenic syndrome and hypotonia-cystinuria, conditions associated with muscle weakness and fatigability. This study may help decoding the genetic architecture behind disease heterogeneity, creating avenues for personalised therapeutic approaches based on genetic background.; Cell and molecular biology; Epidemiology; Pulmonary function testing; General respiratory patient care; Physiology
  • ||||||||||  PROGNOSTIC FACTORS IN OPERATED THYMOMA. (PS-11 in poster area) -  Jun 17, 2023 - Abstract #ERS2023ERS_485;    
    This justifies the importance of conducting larger studies. Only the knowledge of these prognostic factors can improve the management and thus the survival of patients operated for thymoma.; Surgery; Epidemiology; Respiratory intensive care; Endoscopy and interventional pulmonology; Imaging; Pulmonary function testing
  • ||||||||||  cyclophosphamide / Generic mfg.
    Journal:  Experience of Peripheral Blood CD34+ Stem Cells Collection in Autoimmune Patients. (Pubmed Central) -  Jun 16, 2023   
    Only the knowledge of these prognostic factors can improve the management and thus the survival of patients operated for thymoma.; Surgery; Epidemiology; Respiratory intensive care; Endoscopy and interventional pulmonology; Imaging; Pulmonary function testing Very first attempts in mobilizing, harvesting, and selecting CD34+ stem cells were successful, paving the way for autoimmune patients to have autologous hematopoietic stem cell transplantation in Vietnam.
  • ||||||||||  Review, Journal:  Myasthenic crisis. (Pubmed Central) -  Jun 15, 2023   
    The mortality rate in United States cohorts is less than 5% and mortality in MC seems to be driven by age and other medical co-morbidities. MC does not appear to affect long-term prognosis as many patients are able to eventually achieve good MG control.
  • ||||||||||  Journal:  Myasthenia (Pubmed Central) -  Jun 12, 2023   
    The study illustrates the strength of ES in deciphering the genetic basis of rare diseases, contributes to characterization of CMS20 and suggests trends in genotype-phenotype correlation in CMS20. No abstract available
  • ||||||||||  Review, Journal:  Myasthenia in adults, children, and adolescents: what's new? (Pubmed Central) -  Jun 12, 2023   
    In highly active courses of MG with Abs against the muscle-specific receptor tyrosine kinase (MuSK), the use of rituximab should be considered early in the course of the disease...Despite treatment based on the previous guideline, many MG patients suffer considerable impairment to their quality of life. With the new immunomodulators, there is the possibility of early intensified immunotherapy, which, in contrast to long-term immunosuppressants, can lead to a
  • ||||||||||  Vyvgart (efgartigimod alfa-fcab) / argenx, Broteio
    Efficacy, safety, and tolerability of efgartigimod in AChR-Ab (CC: 2nd Floor Foyer & H-M2: Riverview Lounge; Poster Station 4) -  Jun 12, 2023 - Abstract #CNSF2023CNSF_390;    
    Most TEAEs, including infections, were mild or moderate in severity and did not increase in frequency with recurrent dosing. Long-term treatment (median >1 year) with efgartigimod was well tolerated and associated with clinically meaningful improvements in MG-ADL/QMG scores in AChR-Ab
  • ||||||||||  Vyvgart (efgartigimod alfa-fcab) / argenx, Broteio
    Minimal symptom expression following treatment with efgartigimod in patients with Generalized Myasthenia Gravis (CC: 2nd Floor Foyer & H-M2: Riverview Lounge; Poster Station 4) -  Jun 12, 2023 - Abstract #CNSF2023CNSF_380;    
    In patients with severe refractory anti-MuSK MG, it may be reasonable to consider HSCT but with an appreciation of the associated risks. Efgartigimod treatment resulted in more patients with AChR-Ab+ gMG achieving both MSE and clinically meaningful MG-ADL improvements.
  • ||||||||||  Vyvgart (efgartigimod alfa-fcab) / argenx, Broteio
    Lunch 'n Learn: New Frontiers in the management of myasthenia gravis (H-M2: Alberta) -  Jun 12, 2023 - Abstract #CNSF2023CNSF_131;    
    It is an unaccredited learning activity and not eligible for MOC credits. Learning Objectives: Understand the evolving treatment landscape for patients with myasthenia gravis Understand the role of IgG autoantibodies in the pathophysiology of myasthenia gravis Understand the mechanism of action of efgartigimod Understand the medical evidence for efgartigimod in the treatment of patients with myasthenia gravis Learning Objectives: Understand the evolving treatment landscape for patients with myasthenia gravis Understand the role of IgG autoantibodies in the pathophysiology of myasthenia gravis Understand the mechanism of action of efgartigimod Understand the medical evidence for efgartigimod in the treatment of patients with myasthenia gravis
  • ||||||||||  Ultomiris IV (ravulizumab-cwvz IV) / AstraZeneca
    Lunch 'n Learn: New Advances in the Treatment of General Myasthenia Gravis: Expanding the use of Targeted Therapy (H-M2: Alhambra) -  Jun 12, 2023 - Abstract #CNSF2023CNSF_52;    
    It is an unaccredited learning activity and not eligible for MOC credits. Learning Objectives: Define gMG management goals and current strategies Define the role of complement in the pathophysiology of gMG Evaluate the Efficacy and Safety of Ravulizumab in the treatment of (AchR) anti-body positive generalized Myasthenia Gravis Understand how the clinical evidence can be applied in the clinical setting through case discussion Learning Objectives: Define gMG management goals and current strategies Define the role of complement in the pathophysiology of gMG Evaluate the Efficacy and Safety of Ravulizumab in the treatment of (AchR) anti-body positive generalized Myasthenia Gravis Understand how the clinical evidence can be applied in the clinical setting through case discussion
  • ||||||||||  Advances in treatments of hereditary neuromuscular diseases in children and adults (CC: Theatre - 1st Flr) -  Jun 12, 2023 - Abstract #CNSF2023CNSF_3;    
    Gerald Pfeffer) and myasthenic syndromes (Dr. Hanns Lochmuller) Learning Objectives: Understand all available treatment options for children and adults with neuromusuclar disease Understand potential adverse events of treatments to optimize choice of therapy and monitoring Recognize the utility of magnetic resonance imaging and other diagnostic tests evaluating a patient with a neuromuscular disorder Learning Objectives: Understand all available treatment options for children and adults with neuromusuclar disease Understand potential adverse events of treatments to optimize choice of therapy and monitoring Recognize the utility of magnetic resonance imaging and other diagnostic tests evaluating a patient with a neuromuscular disorder
  • ||||||||||  OUTCOMES OF THERAPEUTIC PLASMA EXCHANGE: A ONE-YEAR EXPERIENCE IN INTERNAL MEDICINE INTENSIVE CARE UNIT (ePoster (Virtual Only)) -  Jun 9, 2023 - Abstract #ERAEDTA2023ERA_EDTA_2490;    
    However, it showed no significant difference(p?=?0.2754), although the EBV infection rate was higher in the thymomas with myasthenia gravis. According to our experience, membrane therapeutic plasma exchange is a successful and secure treatment for a variety of illnesses including thrombotic microangiopathies, systemic vasculitis, myasthenia gravis, proliferative lupus nephritis, and Guillain-Barr
  • ||||||||||  Retrospective data, Journal, Metastases:  Outcomes of extended resection for locally advanced thymic malignancies. (Pubmed Central) -  Jun 9, 2023   
    In an expert center, extended resection targeting complete resection rather than organ preservation provided good outcomes in patients with locally advanced thymic malignancies. The risk/benefit ratio of surgery should be assessed with special care in patients who are elderly or have myasthenia gravis.
  • ||||||||||  Rystiggo (rozanolixizumab) / UCB
    Trial completion date, Trial primary completion date:  A Study to Evaluate Rozanolixizumab in Study Participants With Generalized Myasthenia Gravis (clinicaltrials.gov) -  Jun 7, 2023   
    P3,  N=165, Active, not recruiting, 
    These results may provide a potential clue for doctors, nurses, and other caregivers to optimise treatment strategies for targeted patients with MG. Trial completion date: Oct 2023 --> Jan 2024 | Trial primary completion date: Oct 2023 --> Jan 2024